CS MEDICA's Subsidiary Signs Agreement to Target the German Market, Leveraging Expertise of Nimbus Health, a Dr. Reddy's Laboratories company.

CANNORDIC Collaborates with Nimbus Health GmbH, a Specialist in Medical Cannabis, to Enhance Patient Care in Germany

CS MEDICA, a pioneer in MedTech specializing in pain management, autoimmune diseases, and stress-related disorders with its compliant CBD-infused medical treatments, is pleased to announce a strategic partnership between its subsidiary CANNORDIC A/S and Nimbus Health GmbH, a German provider specializing in prescription-based, medical cannabis treatments.

This partnership will enable the integration of pain management focused medical device products from CANNORDIC into Nimbus Health's branded portfolio, expanding access to compliant, CBD-infused therapies. Targeting the German market is pivotal for CS MEDICA as it represents the largest market for self-care approaches, where CBD usage is mature, and consumer knowledge is exceptionally high, leading to increasing demand for evidence-based products.

Lone Henriksen, CEO of CS MEDICA, states, "This partnership represents a significant advancement in our mission to enhance access to scientifically validated, CBD-infused products. Incorporating our proven formulations under Nimbus's brand will address the growing patient demand for effective and reliable medical cannabinoid therapies."

Lone continues: "We began our discussions over a year ago. Our engagement with a partner as Nimbus Health, a Dr. Reddy's Laboratories company, that prioritizes patient safety, compliance, and accessibility has enriched our processes and commercial strategies."

Ozan Temizkan, Managing Director of Nimbus Health, states: "As a company, we are committed to accelerating access to cannabinoid-based medicines for German patients. In this effort, we constantly look for complementary products to expand our offering to meet patients' needs, especially in pain management. That is why Cannordic's CBD-infused pain patch will be an important product in our portfolio."

The selected product will be rebranded under Nimbus Health's label and will be available online under the healthcare line RHYZAX® from January 2025 in Germany, with a potential market expansion later.